Non-invasive early detection of cancer four years before conventional diagnosis using a blood test.
Xingdong Chen,Jeffrey A. Gole,Athurva Gore,He Qiye,Ming Lu,Ming Lu,Jun Min,Ziyu Yuan,Xiaorong Yang,Xiaorong Yang,Yanfeng Jiang,Tiejun Zhang,Chen Suo,Xiaojie Li,Lei Cheng,Zhenhua Zhang,Hongyu Niu,Zhe Li,Zhen Xie,Han Shi,Xiang Zhang,Min Fan,Xiaofeng Wang,Yajun Yang,Justin Dang,Catie McConnell,Juan Zhang,Jiucun Wang,Shun-Zhang Yu,Weimin Ye,Weimin Ye,Yuan Gao,Kun Zhang,Rui Liu,Li Jin +34 more
TLDR
It is demonstrated that cancer can be non-invasively detected up to four years before current standard of care and patients whose disease is diagnosed in its early stages have better outcomes.Abstract:
Early detection has the potential to reduce cancer mortality, but an effective screening test must demonstrate asymptomatic cancer detection years before conventional diagnosis in a longitudinal study. In the Taizhou Longitudinal Study (TZL), 123,115 healthy subjects provided plasma samples for long-term storage and were then monitored for cancer occurrence. Here we report the preliminary results of PanSeer, a noninvasive blood test based on circulating tumor DNA methylation, on TZL plasma samples from 605 asymptomatic individuals, 191 of whom were later diagnosed with stomach, esophageal, colorectal, lung or liver cancer within four years of blood draw. We also assay plasma samples from an additional 223 cancer patients, plus 200 primary tumor and normal tissues. We show that PanSeer detects five common types of cancer in 88% (95% CI: 80–93%) of post-diagnosis patients with a specificity of 96% (95% CI: 93–98%), We also demonstrate that PanSeer detects cancer in 95% (95% CI: 89–98%) of asymptomatic individuals who were later diagnosed, though future longitudinal studies are required to confirm this result. These results demonstrate that cancer can be non-invasively detected up to four years before current standard of care. Patients whose disease is diagnosed in its early stages have better outcomes. In this study, the authors develop a non invasive blood test based on circulating tumor DNA methylation that can potentially detect cancer occurrence even in asymptomatic patients.read more
Citations
More filters
Journal ArticleDOI
Advances in bladder cancer biology and therapy
TL;DR: Recent developments in the molecular and translational aspects of bladder cancer biology are examined and their current or potential future clinical applications in the management of bladdercancer are discussed.
Journal ArticleDOI
Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.
Eric A. Klein,Donald A. Richards,Allen Lee Cohn,M.K. Tummala,Rosanna Lapham,David Cosgrove,G. Chung,Jessica M. Clement,Jianjun Gao,Nathan Hunkapiller,Arash Jamshidi,Kathryn N. Kurtzman,Michael V. Seiden,Charles Swanton,Minetta C. Liu +14 more
TL;DR: In this article, a multi-cancer early detection (MCED) test was proposed to detect cancer signals across multiple cancer types and predict cancer signal origin (CSO) with high accuracy.
Journal ArticleDOI
Review on Strategies and Technologies for Exosome Isolation and Purification
TL;DR:
Journal ArticleDOI
Cancer evolution: Darwin and beyond
TL;DR: The role of macroevolutionary events in cancer initiation and progression is discussed in this paper, where the authors highlight clinical opportunities which can be grasped through targeting cancer vulnerabilities arising from non-Darwinian patterns of evolution.
Journal ArticleDOI
Cancer nanotechnology: current status and perspectives.
Jessica A. Kemp,Young Jik Kwon +1 more
TL;DR: Nanotechnological applications for cancer drug therapy, diagnostics, imaging, and radiation therapy are reviewed in this article, where the authors provide insights into the current clinical and pre-clinical nanotechnologies applications.
References
More filters
Journal ArticleDOI
Systematic Review: Process of Forming Academic Service Partnerships to Reform Clinical Education
TL;DR: This study’s findings can provide practical guidelines to steer partnership programs within the academic and clinical bodies, with the aim of providing a collaborative partnership approach to clinical education.
Journal ArticleDOI
Cancer statistics, 2018
TL;DR: The combined cancer death rate dropped continuously from 1991 to 2015 by a total of 26%, translating to approximately 2,378,600 fewer cancer deaths than would have been expected if death rates had remained at their peak.
Journal ArticleDOI
Cancer statistics in China, 2015
Wanqing Chen,Rongshou Zheng,Peter D. Baade,Siwei Zhang,Hongmei Zeng,Freddie Bray,Ahmedin Jemal,Xue Qin Yu,Jie He +8 more
TL;DR: Many of the estimated cancer cases and deaths can be prevented through reducing the prevalence of risk factors, while increasing the effectiveness of clinical care delivery, particularly for those living in rural areas and in disadvantaged populations.
Journal ArticleDOI
A review: James H. Meisel, The Fall of the Republic: Military Revolt in France Edward R. Tannenbaum, The Action Française: Diehard Reactionaries in Twentieth-Century France
Journal ArticleDOI
GREAT improves functional interpretation of cis-regulatory regions
Cory Y. McLean,Dave Bristor,Michael Hiller,Shoa L. Clarke,Bruce T. Schaar,Craig B. Lowe,Aaron M. Wenger,Gill Bejerano +7 more
TL;DR: The Genomic Regions Enrichment of Annotations Tool (GREAT) is developed to analyze the functional significance of cis-regulatory regions identified by localized measurements of DNA binding events across an entire genome.
Related Papers (5)
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Joshua D. Cohen,Lu Li,Yuxuan Wang,Christopher J. Thoburn,Bahman Afsari,Ludmila Danilova,Christopher Douville,Ammar A. Javed,Fay Wong,Austin Mattox,Ralph H. Hruban,Ralph H. Hruban,Christopher L. Wolfgang,Michael Goggins,Marco Dal Molin,Tian Li Wang,Tian Li Wang,Richard B.S. Roden,Richard B.S. Roden,Alison P. Klein,Alison P. Klein,Janine Ptak,Lisa Dobbyn,Joy Schaefer,Natalie Silliman,Maria Popoli,Joshua T. Vogelstein,J.D. Browne,Robert E. Schoen,Randall E. Brand,Jeanne Tie,Peter Gibbs,Hui-Li Wong,Aaron S. Mansfield,Jin Jen,Samir M. Hanash,Massimo Falconi,Peter J. Allen,Shibin Zhou,Chetan Bettegowda,Luis A. Diaz,Cristian Tomasetti,Cristian Tomasetti,Kenneth W. Kinzler,Bert Vogelstein,Anne Marie Lennon,Nickolas Papadopoulos +46 more
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda,Chetan Bettegowda,Mark Sausen,Rebecca J. Leary,Isaac Kinde,Yuxuan Wang,Nishant Agrawal,Nishant Agrawal,Bjarne Bartlett,Bjarne Bartlett,Hao Wang,Brandon Luber,Rhoda M. Alani,Emmanuel S. Antonarakis,Nilofer S. Azad,Alberto Bardelli,Henry Brem,John L. Cameron,Clarence Lee,Leslie A. Fecher,Leslie A. Fecher,Gary L. Gallia,Peter Gibbs,Dung T. Le,Dung T. Le,Robert L. Giuntoli,Michael Goggins,Michael D. Hogarty,Matthias Holdhoff,Seung-Mo Hong,Seung-Mo Hong,Yuchen Jiao,Hartmut Juhl,Jenny J. Kim,Giulia Siravegna,Daniel A. Laheru,Calogero Lauricella,Michael Lim,Evan J. Lipson,Suely Kazue Nagahashi Marie,George J. Netto,Kelly S. Oliner,Alessandro Olivi,Louise Olsson,Gregory J. Riggins,Andrea Sartore-Bianchi,Kerstin Schmidt,le-Ming Shih,Sueli Mieko Oba-Shinjo,Salvatore Siena,Dan Theodorescu,Jeanne Tie,Timothy T. Harkins,Silvio Veronese,Tian Li Wang,Jon D. Weingart,Christopher L. Wolfgang,Laura D. Wood,Dongmei Xing,Ralph H. Hruban,Jian Wu,Peter J. Allen,C. Max Schmidt,Michael A. Choti,Victor E. Velculescu,Kenneth W. Kinzler,Bert Vogelstein,Nickolas Papadopoulos,Luis A. Diaz,Luis A. Diaz +69 more